NEW
YORK, March 3, 2025 /PRNewswire/
-- Immunic, Inc. (Nasdaq: IMUX), a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases, today announced participation in the following
scientific and investor conferences in March:
- March 4-7: 34th
Annual Meeting of the Society for Virology. Two abstracts have
been accepted for abstract talk presentations at this conference in
Hamburg, Germany. The
presentations will be accessible on the "Events and Presentations"
section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Title: Orally Bioavailable RORγ/DHODH Dual
Host-Targeting Small Molecules with Broad-Spectrum Antiviral
Activity
- Presenting Author: Friedrich
Hahn, Ph.D., Institute for Clinical and Molecular Virology,
Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
- Abstract Talk: O 081
- Session: Antiviral therapy and resistance I
- Date: March 6, 2025
- Time: 9:30-9:45 am CET (3:30-3:45am ET)
- Title: Novel Vidofludimus-Based DHODH Inhibitors
Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum
Antiviral Activity
- Presenting Author: Alexandra
Herrmann, Ph.D., Manager Translational Pharmacology,
Immunic
- Abstract Talk: O 112
- Session: Antiviral therapy and resistance II
- Date: March 7, 2025
- Time: 11:00-11:15am CET
(5:00-5:15am ET)
- March 10-12: Leerink Partners
Global Healthcare Conference. Daniel
Vitt, Ph.D., Chief Executive Officer of Immunic, will
participate in a fireside chat on Wednesday,
March 12, at 10:00 am ET
during this conference in Miami. A
webcast will be available on the "Events and Presentations" section
of Immunic's website at:
https://ir.imux.com/events-and-presentations.
Dr. Vitt, Glenn Whaley, Chief
Financial Officer, and Jessica Breu,
Vice President Investor Relations and Communications, will also
participate in one-on-one investor meetings at the conference. To
schedule a meeting, please contact your Leerink representative or
Jessica Breu at:
jessica.breu@imux.com.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases. The company's lead development program,
vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2
clinical trials for the treatment of relapsing and progressive
multiple sclerosis, respectively, and has shown therapeutic
activity in phase 2 clinical trials in patients suffering from
relapsing-remitting multiple sclerosis, progressive multiple
sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus
calcium combines neuroprotective effects, through its mechanism as
a first-in-class nuclear receptor-related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease as well as
inflammatory bowel disease, Graft-versus-Host-Disease and
weight management. IMU-381, which currently is in preclinical
testing, is a next generation molecule being developed to
specifically address the needs of gastrointestinal diseases. For
further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, sufficiency of cash and cash
runway, expected timing, development and results of clinical
trials, prospects, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to management's and
employee's participation in scientific and investor conferences.
Immunic may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management's current expectations and involve substantial risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, increasing inflation, impacts of the
Ukraine – Russia conflict and the conflict in the
Middle East on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, including the
ability to satisfy the minimum average price and trading volume
conditions required to receive funding in tranche 2 and 3 of the
January 2024 private placement, the
fact that the results of earlier preclinical studies and clinical
trials may not be predictive of future clinical trial results, any
changes to the size of the target markets for the Company's
products or product candidates, the protection and market
exclusivity provided by Immunic's intellectual property, risks
related to the drug development and the regulatory approval process
and the impact of competitive products and technological changes. A
further list and descriptions of these risks, uncertainties and
other factors can be found in the section captioned "Risk Factors,"
in the company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2023, filed with
the SEC on February 22, 2024, and in
the company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this
release. Immunic disclaims any intent or obligation to update these
forward-looking statements to reflect events or circumstances that
exist after the date on which they were made. Immunic expressly
disclaims all liability in respect to actions taken or not taken
based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-investor-conferences-in-march-302386106.html
SOURCE Immunic, Inc.
